Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia: Research paper

British Journal of Haematology

Volumn 150, Issue 6, 2010, Pages 665-673

  Moreno, Daniel Antunes ^a   Scrideli, Carlos Alberto ^a   Cortez, Maria Angélica Abdala ^a   De Paula Queiroz, Rosane ^a   Valera, Elvis Terci ^a   Da Silva Silveira, Vanessa ^a   Yunes, José Andres ^b   Brandalise, Silvia Regina ^b   Tone, Luiz Gonzaga ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

acute lymphoblastic leukaemia; childhood; gene expression; histone deacetylase; prognosis

Indexed keywords

HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 7;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; FEMALE; GENE; GENE EXPRESSION; GENETIC ASSOCIATION; HDAC9 GENE; HUMAN; HUMAN TISSUE; INFANT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS;

ADOLESCENT; BONE MARROW; CHILD; CHILD, PRESCHOOL; FEMALE; GENE EXPRESSION PROFILING; HISTONE DEACETYLASES; HUMANS; INFANT; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 77956309330     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08301.x     Document Type: Article

References (68)

1. Acharya, M.R., Sparreboom, A., Venitz, J. Figg, W.D. (2005) Rational development of histone deacetylase inhibitors as anticancer agents: a review. Molecular Pharmacology, 68, 917 932.
2. Altucci, L. Minucci, S. (2009) Epigenetic therapies in haematological malignancies: searching for true targets. European Journal of Cancer, 45, 1137 1145.
3. Bakin, R.E. Jung, M.O. (2004) Cytoplasmic sequestration of HDAC7 from mitochondrial and nuclear compartments upon initiation of apoptosis. Journal of Biological Chemistry, 279, 51218 51225.
4. Baylin, S.B. Ohm, J.E. (2006) Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nature Reviews. Cancer, 6, 107 116.
5. Bernstein, B.E., Meissner, A. Lander, E.S. (2007) The mammalian epigenome. Cell, 128, 669 681.
6. Blum, K.A., Advani, A., Fernandez, L., Van Der Jagt, R., Brandwein, J., Kambhampati, S., Kassis, J., Davis, M., Bonfils, C., Dubay, M., Dumouchel, J., Drouin, M., Lucas, D.M., Martell, R.E. Byrd, J.C. (2009) Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia. British Journal Haematology, 147, 507 514.
7. Bradbury, C.A., Khanim, F.L., Hayden, R., Bunce, C.M., White, D.A., Drayson, M.T., Craddock, C. Turner, B.M. (2005) Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia, 19, 1751 1759.
8. Brandalise, S.R., Pinheiro, V.R., Aguiar, S.S., Matsuda, E.I., Otubo, R., Yunes, J.A., Pereira, W.V., Carvalho, E.G., Cristofani, L.M., Souza, M.S., Lee, M.L., Dobbin, J.A., Pombo-de-Oliveira, M.S., Lopes, L.F., Melnikoff, K.N., Brunetto, A.L., Tone, L.G., Scrideli, C.A., Morais, V.L. Viana, M.B. (2010) Benefits of the intermittent use of 6-mercaptopurine and methotrexate in maintenance treatment for low-risk acute lymphoblastic leukemia in children: randomized trial from the Brazilian Childhood Cooperative Group - Protocol ALL-99. Journal of Clinical Oncology, in press, doi/10.1200/JCO.2009.25.6115.
9. Byrd, J.C., Marcucci, G., Parthun, M.R., Xiao, J.J., Klisovic, R.B., Moran, M., Lin, T.S., Liu, S., Sklenar, A.R., Davis, M.E., Lucas, D.M., Fischer, B., Shank, R., Tejaswi, S.L., Binkley, P., Wright, J., Chan, K.K. Grever, M.R. (2005) A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood, 105, 959 967.
10. Choi, Y.W., Bae, S.M., Kim, Y.W., Lee, H.N., Kim, Y.W., Park, T.C., Ro, D.Y., Shin, J.C., Shin, S.J., Seo, J.S. Ahn, W.S. (2007) Gene expression profiles in squamous cell cervical carcinoma using array-based comparative genomic hybridization analysis. International Journal Of Gynecological Cancer, 17, 687 696.
11. Cortez, M.A., Scrideli, C.A., Yunes, J.A., Valera, E.T., Toledo, S.R., Pavoni-Ferreira, P.C., Lee, M.L., Petrilli, A.S., Brandalise, S.R. Tone, L.G. (2009) mRNA expression profile of multidrug resistance genes in childhood acute lymphoblastic leukemia. Low expression levels associated with a higher risk of toxic death. Pediatric Blood & Cancer, 53, 996 1004.
12. Cress, W.D. Seto, E. (2000) Histone deacetylases, transcriptional control, and cancer. Journal of Cellular Physiology, 184, 1 16.
13. Ducasse, M. Brown, M.A. (2006) Epigenetic aberrations and cancer. Molecular Cancer, 5, 60.
14. Esau, C., Boes, M., Youn, H.D., Tatterson, L., Liu, J.O. Chen, J. (2001) Deletion of calcineurin and myocyte enhancer factor 2 (MEF2) binding domain of Cabin1 results in enhanced cytokine gene expression in T cells. Journal of Experimental Medicine, 194, 1449 1459.
15. Gallinari, P., Di Marco, S., Jones, P., Pallaoro, M. Steinkuhler, C. (2007) HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics. Cell Research, 17, 195 211.
16. Galm, O., Herman, J.G. Baylin, S.B. (2006) The fundamental role of epigenetics in hematopoietic malignancies. Blood Reviews, 20, 1 13.
17. Garcia-Manero, G., Assouline, S., Cortes, J., Estrov, Z., Kantarjian, H., Yang, H., Newsome, W.M., Miller, Jr., W.H., Rousseau, C., Kalita, A., Bonfils, C., Dubay, M., Patterson, T.A., Li, Z., Besterman, J.M., Reid, G., Laille, E., Martell, R.E. Minden, M. (2008) Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood, 112, 981 989.
18. Gloghini, A., Buglio, D., Khaskhely, N.M., Georgakis, G., Orlowski, R.Z., Neelapu, S.S., Carbone, A. Younes, A. (2009) Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors. British Journal Haematology, 147, 515 525.
19. Glozak, M.A. Seto, E. (2007) Histone deacetylases and cancer. Oncogene, 26, 5420 5432.
20. Gruffat, H., Manet, E. Sergeant, A. (2002) MEF2-mediated recruitment of class II HDAC at the EBV immediate early gene BZLF1 links latency and chromatin remodeling. EMBO Reports, 3, 141 146.
21. Holleman, A., Cheok, M.H., den Boer, M.L., Yang, W., Veerman, A.J., Kazemier, K.M., Pei, D., Cheng, C., Pui, C.H., Relling, M.V., Janka-Schaub, G.E., Pieters, R. Evans, W.E. (2004) Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. New England Journal of Medicine, 351, 533 542.
22. Holliday, R. (2006) Epigenetics: a historical overview. Epigenetics, 1, 76 80.
23. Karagianni, P. Wong, J. (2007) HDAC3: taking the SMRT-N-CoRrect road to repression. Oncogene, 26, 5439 5449.
24. Kato, H., Tamamizu-Kato, S. Shibasaki, F. (2004) Histone deacetylase 7 associates with hypoxia-inducible factor 1alpha and increases transcriptional activity. Journal of Biological Chemistry, 279, 41966 41974.
25. Kim, Y. Tian, M. (2009) NF-kappaB family of transcription factor facilitates gene conversion in chicken B cells. Molecular Immunology, 46, 3283 3291.
26. Kim, D.H., Kim, M. Kwon, H.J. (2003) Histone deacetylase in carcinogenesis and its inhibitors as anti-cancer agents. Journal of Biochemistry and Molecular Biology, 36, 110 119.
27. Klimek, V.M., Fircanis, S., Maslak, P., Guernah, I., Baum, M., Wu, N., Panageas, K., Wright, J.J., Pandolfi, P.P. Nimer, S.D. (2008) Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes. Clinical Cancer Research, 14, 826 832.
28. Krusche, C.A., Wulfing, P., Kersting, C., Vloet, A., Bocker, W., Kiesel, L., Beier, H.M. Alfer, J. (2005) Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis. Breast Cancer Research and Treatment, 90, 15 23.
29. Lane, A.A. Chabner, B.A. (2009) Histone deacetylase inhibitors in cancer therapy. Journal of Clinical Oncology, 27, 5459 5468.
30. Livak, K.J. Schmittgen, T.D. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 25, 402 408.
31. Lu, Q., Qiu, X., Hu, N., Wen, H., Su, Y. Richardson, B.C. (2006) Epigenetics, disease, and therapeutic interventions. Ageing Research Reviews, 5, 449 467.
32. Lucio-Eterovic, A.K., Cortez, M.A., Valera, E.T., Motta, F.J., Queiroz, R.G., Machado, H.R., Carlotti, Jr., C.G., Neder, L., Scrideli, C.A. Tone, L.G. (2008) Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue: class II and IV are hypoexpressed in glioblastomas. BMC Cancer, 8, 243.
33. Mann, B.S., Johnson, J.R., Cohen, M.H., Justice, R. Pazdur, R. (2007) FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist, 12, 1247 1252.
34. Marks, P., Rifkind, R.A., Richon, V.M., Breslow, R., Miller, T. Kelly, W.K. (2001) Histone deacetylases and cancer: causes and therapies. Nature Reviews. Cancer, 1, 194 202.
35. Marquard, L., Gjerdrum, L.M., Christensen, I.J., Jensen, P.B., Sehested, M. Ralfkiaer, E. (2008) Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma. Histopathology, 53, 267 277.
36. Marquard, L., Poulsen, C.B., Gjerdrum, L.M., de Nully Brown, P., Christensen, I.J., Jensen, P.B., Sehested, M., Johansen, P. Ralfkiaer, E. (2009) Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas. Histopathology, 54, 688 698.
37. Matthews, S.A., Liu, P., Spitaler, M., Olson, E.N., McKinsey, T.A., Cantrell, D.A. Scharenberg, A.M. (2006) Essential role for protein kinase D family kinases in the regulation of class II histone deacetylases in B lymphocytes. Molecular and Cellular Biology, 26, 1569 1577.
38. Melnick, A. Licht, J.D. (2002) Histone deacetylases as therapeutic targets in hematologic malignancies. Current Opinion in Hematology, 9, 322 332.
39. Minucci, S. Pelicci, P.G. (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nature Reviews. Cancer, 6, 38 51.
40. Nakagawa, M., Oda, Y., Eguchi, T., Aishima, S., Yao, T., Hosoi, F., Basaki, Y., Ono, M., Kuwano, M., Tanaka, M. Tsuneyoshi, M. (2007) Expression profile of class I histone deacetylases in human cancer tissues. Oncology Reports, 18, 769 774.
41. Olsen, E.A., Kim, Y.H., Kuzel, T.M., Pacheco, T.R., Foss, F.M., Parker, S., Frankel, S.R., Chen, C., Ricker, J.L., Arduino, J.M. Duvic, M. (2007) Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. Journal of Clinical Oncology, 25, 3109 3115.
42. Osada, H., Tatematsu, Y., Saito, H., Yatabe, Y., Mitsudomi, T. Takahashi, T. (2004) Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients. International Journal of Cancer, 112, 26 32.
43. Ouaissi, M., Sielezneff, I., Silvestre, R., Sastre, B., Bernard, J.P., Lafontaine, J.S., Payan, M.J., Dahan, L., Pirro, N., Seitz, J.F., Mas, E., Lombardo, D. Ouaissi, A. (2008) High histone deacetylase 7 (HDAC7) expression is significantly associated with adenocarcinomas of the pancreas. Annals of Surgical Oncology, 15, 2318 2328.
44. Petrie, K., Guidez, F., Howell, L., Healy, L., Waxman, S., Greaves, M. Zelent, A. (2003) The histone deacetylase 9 gene encodes multiple protein isoforms. Journal of Biological Chemistry, 278, 16059 16072.
45. Rao, S., Karray, S., Gackstetter, E.R. Koshland, M.E. (1998) Myocyte enhancer factor-related B-MEF2 is developmentally expressed in B cells and regulates the immunoglobulin J chain promoter. Journal of Biological Chemistry, 273, 26123 26129.
46. Romanski, A., Bacic, B., Bug, G., Pfeifer, H., Gul, H., Remiszewski, S., Hoelzer, D., Atadja, P., Ruthardt, M. Ottmann, O.G. (2004) Use of a novel histone deacetylase inhibitor to induce apoptosis in cell lines of acute lymphoblastic leukemia. Haematologica, 89, 419 426.
47. Ropero, S. Esteller, M. (2007) The role of histone deacetylases (HDACs) in human cancer. Molecular Oncology, 1, 19 25.
48. Ross, M.E., Zhou, X., Song, G., Shurtleff, S.A., Girtman, K., Williams, W.K., Liu, H.C., Mahfouz, R., Raimondi, S.C., Lenny, N., Patel, A. Downing, J.R. (2003) Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood, 102, 2951 2959.
49. Sakajiri, S., Kumagai, T., Kawamata, N., Saitoh, T., Said, J.W. Koeffler, H.P. (2005) Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. Experimental Hematology, 33, 53 61.
50. dos Santos, M.P., Schwartsmann, G., Roesler, R., Brunetto, A.L. Abujamra, A.L. (2009) Sodium butyrate enhances the cytotoxic effect of antineoplastic drugs in human lymphoblastic T-cells. Leukemia Research, 33, 218 221.
51. Sasaki, K., Yamagata, T. Mitani, K. (2008) Histone deacetylase inhibitors trichostatin A and valproic acid circumvent apoptosis in human leukemic cells expressing the RUNX1 chimera. Cancer Science, 99, 414 422.
52. Satyaraj, E. Storb, U. (1998) Mef2 proteins, required for muscle differentiation, bind an essential site in the Ig lambda enhancer. Journal of Immunology, 161, 4795 4802.
53. Scrideli, C.A., Assumpcao, J.G., Ganazza, M.A., Araujo, M., Toledo, S.R., Lee, M.L., Delbuono, E., Petrilli, A.S., Queiroz, R.P., Biondi, A., Viana, M.B., Yunes, J.A., Brandalise, S.R. Tone, L.G. (2009) A simplified minimal residual disease polymerase chain reaction method at early treatment points can stratify children with acute lymphoblastic leukemia into good and poor outcome groups. Haematologica, 94, 781 789.
54. Swanson, B.J., Jack, H.M. Lyons, G.E. (1998) Characterization of myocyte enhancer factor 2 (MEF2) expression in B and T cells: MEF2C is a B cell-restricted transcription factor in lymphocytes. Molecular Immunology, 35, 445 458.
55. Tsapis, M., Lieb, M., Manzo, F., Shankaranarayanan, P., Herbrecht, R., Lutz, P. Gronemeyer, H. (2007) HDAC inhibitors induce apoptosis in glucocorticoid-resistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway. International Journal of Biochemistry and Cell Biology, 39, 1500 1509.
56. Verdin, E., Dequiedt, F. Kasler, H.G. (2003) Class II histone deacetylases: versatile regulators. Trends in Genetics, 19, 286 293.
57. Wang, L., de Zoeten, E.F., Greene, M.I. Hancock, W.W. (2009) Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells. Nature Reviews. Drug Discovery, 8, 969 981.
58. Weichert, W. (2009) HDAC expression and clinical prognosis in human malignancies. Cancer Letters, 280, 168 176.
59. Weichert, W., Denkert, C., Noske, A., Darb-Esfahani, S., Dietel, M., Kalloger, S.E., Huntsman, D.G. Kobel, M. (2008a) Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas. Neoplasia, 10, 1021 1027.
60. Weichert, W., Roske, A., Gekeler, V., Beckers, T., Ebert, M.P., Pross, M., Dietel, M., Denkert, C. Rocken, C. (2008b) Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. The Lancet Oncology, 9, 139 148.
61. Weichert, W., Roske, A., Gekeler, V., Beckers, T., Stephan, C., Jung, K., Fritzsche, F.R., Niesporek, S., Denkert, C., Dietel, M. Kristiansen, G. (2008c) Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. British Journal of Cancer, 98, 604 610.
62. Weichert, W., Roske, A., Niesporek, S., Noske, A., Buckendahl, A.C., Dietel, M., Gekeler, V., Boehm, M., Beckers, T. Denkert, C. (2008d) Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clinical Cancer Research, 14, 1669 1677.
63. Witt, O., Deubzer, H.E., Milde, T. Oehme, I. (2009) HDAC family: what are the cancer relevant targets? Cancer Letters, 277, 8 21.
64. Yang, X., Huang, Y., Chen, J.L., Xie, J., Sun, X. Lussier, Y.A. (2009) Mechanism-anchored profiling derived from epigenetic networks predicts outcome in acute lymphoblastic leukemia. BMC Bioinformatics, 10 (Suppl. 9 S6.
65. Youn, H.D. Liu, J.O. (2000) Cabin1 represses MEF2-dependent Nur77 expression and T cell apoptosis by controlling association of histone deacetylases and acetylases with MEF2. Immunity, 13, 85 94.
66. Youn, H.D., Sun, L., Prywes, R. Liu, J.O. (1999) Apoptosis of T cells mediated by Ca2+-induced release of the transcription factor MEF2. Science, 286, 790 793.
67. Youn, H.D., Chatila, T.A. Liu, J.O. (2000) Integration of calcineurin and MEF2 signals by the coactivator p300 during T-cell apoptosis. EMBO Journal, 19, 4323 4331.
68. Zhou, X., Marks, P.A., Rifkind, R.A. Richon, V.M. (2001) Cloning and characterization of a histone deacetylase, HDAC9. Proceedings of the National Academy of Sciences of the United States of America, 98, 10572 10577.